Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Assessment of cutaneous toxcitiy in cancer patients treated with CDK 4/6 inhibitors and endocrine therapy according to patient-related outcomes at the University Hospital for tumors (CROSBI ID 734137)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Jakšić, Petra ; Linarić, Petra ; Jezernik, Dejana ; Kanceljak, Kristina ; Tečić Vuger, Ana ; Pavlović Mavić, Mirjana ; Vazdar, Ljubica ; Šeparović, Robert Assessment of cutaneous toxcitiy in cancer patients treated with CDK 4/6 inhibitors and endocrine therapy according to patient-related outcomes at the University Hospital for tumors // Libri oncologici : Croatian journal of oncology. 2022. str. 88-89

Podaci o odgovornosti

Jakšić, Petra ; Linarić, Petra ; Jezernik, Dejana ; Kanceljak, Kristina ; Tečić Vuger, Ana ; Pavlović Mavić, Mirjana ; Vazdar, Ljubica ; Šeparović, Robert

engleski

Assessment of cutaneous toxcitiy in cancer patients treated with CDK 4/6 inhibitors and endocrine therapy according to patient-related outcomes at the University Hospital for tumors

Cyclin-dependent kinases 4/6 inhibitors (CDKi), abemaciclib, ribociclib, and palbociclib, along with endocrine therapy are standard of care in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer.This specific therapy improves treatment outcomes for this defined population adjacent to a manageable toxicity profile. This analysis of real-life clinical practice has asserted that cutaneous toxicity is prevalent in this observed population also announced the requirement for enhanced compassion of symptoms experienced by patients on this specific treatment.

CDKi, cutaneous toxicity, rash

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

88-89.

2022.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Libri oncologici : Croatian journal of oncology

0300-8142

2584-3826

Podaci o skupu

15. Hrvatski onkološki kongres

poster

31.03.2022-03.04.2022

Opatija, Hrvatska

Povezanost rada

Kliničke medicinske znanosti

Poveznice